BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...
Zacks Investment Research on MSN3d
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study
BioMarin BMRN has announced positive results from the phase III PEGASUS study evaluating Palynziq (pegvaliase) in adolescents aged 12-17 years with phenylketonuria (PKU). The study achieved its ...
MPR2d
Pegvaliase Reduces Blood Phenylalanine Levels in Adolescents With PKU
Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.
Clinical Trials Arena on MSN3d
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint
BioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its ...
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
Pharmabiz3d
BioMarin Pharma’s phase 3 PEGASUS trial evaluating Palynziq in adolescents with phenylketonuria meets primary efficacy endpoint
San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...
BioMarin: Phase 3 PEGASUS trial of Palynziq met primary endpoint
Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a ...
Medindia3d
BioMarin Announces Positive Pivotal Data for PALYNZIQ (pegvaliase-pqpz) in Adolescents with Phenylketonuria
PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...
Nasdaq4d
BioMarin's Phase 3 PEGASUS Study Of Palynziq In Adolescents With Phenylketonuria Meets Primary Goal
(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) Wednesday said its Phase 3 PEGASUS study evaluating Palynziq in adolescents aged 12-17 with phenylketonuria (PKU) met its primary goal. The study is ...